Drugmakers and clinical research providers that aim to boost people’s well-being worldwide are displaying healthy stock price performance themselves.

Ethical drugmakers topped the 197 industry groups tracked by IBD in Monday’s issue, just like they did in the prior six weeks. Leaders hail from around the globe.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of six stocks in the group with a highest-possible Composite Rating of 99. The Ireland-based company’s portfolio includes its flagship narcolepsy drug Xyrem, which accounted for 65% of revenue last year, and leukemia drug Erwinaze, which chipped in 20% of sales.

To read more, please click HERE.